Skip to main content

Table 2 Characteristics of JIA patients at baseline, and at the 1-year, 2-year, and 3-year follow-up (FU)

From: The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON)

  Baseline 1-year FU 2-year FU 3-year-FU
n 953 850 805 761
JIA categories
 Oligoarthritis, n (%) 441 (46.3%)
 Persistent oligoarthritis, n (%)   315 (37.1%) 253 (33.3%)
 Extended oligoarthritis, n (%)   74 (8.7%) 98 (12.9%)
 RF-negative polyarthritis, n (%) 250 (26.2%) 226 (26.6%) 205 (27.0%)
 RF-positive polyarthritis, n (%) 16 (1.7%) 15 (1.8%) 15 (2.0%)
 Enthesitis-related arthritis, n (%) 100 (10.5%) 92 (10.8%) 75 (9.9%)
 Psoriatic arthritis, n (%) 40 (4.2%) 41 (4.8%) 35 (4.6%)
 Systemic-onset JIA, n (%) 35 (3.7%) 29 (3.4%) 28 (3.7%)
 Undifferentiated arthritis, n (%) 71 (7.5%) 58 (6.9%) 51 (6.7%)
Disease activity
 PGA (NRS 0–10), mean (SD) 3.8 (2.6) 1.0 (1.5) 0.8 (1.4) 0.8 (1.3)
 cJADAS-10 (0–30), mean (SD) 9.8 (6.2) 3.4 (4.0) 2.8 (3.4) 2.7 (3.6)
 Inactive disease, n (%) 56 (6.0%) 288 (39.8%) 309 (46.8%) 297 (52.0%)
 Minimal disease activity, n (%) 24 (2.6%) 89 (12.3%) 85 (12.9%) 64 (11.2%)
 Moderate disease activity, n (%) 159 (17.0%) 218 (30.2%) 175 (26.5%) 132 (23.1%)
 High disease activity, n (%) 698 (74.5%) 128 (17.7%) 92 (13.9%) 78 (13.7%)
Parent’s reported outcomes
 Functional status (CHAQ; range 0–3), mean (SD) 0.6 (0.7) 0.3 (0.5) 0.2 (0.5) 0.2 (0.5)
 FaBel (total scale; range 0–4), mean (SD)a 1.7 (0.4)
Treatment
 NSAIDs, n (%) 800 (84.0%) 289 (37.8%) 191 (26.1%) 150 (22.4%)
 Systemic glucocorticoids, n (%) 230 (24.1%) 83 (10.9%) 49 (6.7%) 32 (4.8%)
 DMARDs, n (%) 394 (41.3%) 493 (64.5%) 427 (58.3%) 390 (58.2%)
  csDMARDs, n (%) 387 (40.6%) 454 (59.4%) 350 (47.8%) 313 (46.7%)
   MTX, n (%) 364 (38.2%) 422 (55.2%) 324 (44.2%) 285 (42.5%)
   Sulfasalazine, n (%) 19 (2%) 22 (2.9%) 12 (1.6%) 11 (1.6%)
  bDMARDs, n (%) 38 (4.0%) 156 (20.4%) 179 (24.4%) 163 (24.3%)
   Etanercept, n (%) 21 (2.2%) 86 (11.3%) 105 (14.3%) 86 (12.8%)
   Adalimumab, n (%) 7 (0.7%) 35 (4.6%) 37 (5.1%) 46 (6.9%)
  1. bDMARD, biologic DMARD; CHAQ, Childhood Health Assessment Questionnaire; cJADAS-10, clinical Juvenile Arthritis Disease Activity Score; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; FaBel, Family Burden Questionnaire; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NRS, numeric rating scale; NSAID, nonsteroidal anti-inflammatory drug; PGA, physician’s global assessment of disease activity; RF, rheumatoid factor; SD, standard deviation
  2. aReported 3 months after baseline